Nephrology Dialysis Transplantation最新文献

{"title":"Obinutuzumab for the management of immune-mediated glomerular diseases.","authors":"Giovanni M Rossi, Eva Baier, Augusto Vaglio","doi":"10.1093/ndt/gfaf021","DOIUrl":"https://doi.org/10.1093/ndt/gfaf021","url":null,"abstract":"","PeriodicalId":19078,"journal":{"name":"Nephrology Dialysis Transplantation","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143123271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of nutritional vitamin D in CKD-MBD in children and adults with CKD, on dialysis and after kidney transplantation - a European consensus statement.","authors":"Hanne Skou Jørgensen, Marc Vervloet, Etienne Cavalier, Justine Bacchetta, Martin H de Borst, Jordi Bover, Mario Cozzolino, Ana Carina Ferreira, Ditte Hansen, Markus Herrmann, Renate de Jongh, Sandro Mazzaferro, Mandy Wan, Rukshana Shroff, Pieter Evenepoel","doi":"10.1093/ndt/gfae293","DOIUrl":"https://doi.org/10.1093/ndt/gfae293","url":null,"abstract":"<p><p>Vitamin D deficiency is common in patients with chronic kidney disease (CKD) and associates with poor outcomes. Current clinical practice guidelines recommend supplementation with nutritional vitamin D as for the general population. However, recent large-scale, clinical trials in the general population failed to demonstrate a benefit of vitamin D supplementation on skeletal or non-skeletal outcomes, fueling a debate on the rationale for screening for and correcting vitamin D deficiency, both in non-CKD and CKD populations. In a collaboration between the European Renal Osteodystrophy initiative of the European Renal Association (ERA) and the European Society for Paediatric Nephrology (ESPN), an expert panel performed an extensive literature review and formulated clinical practice points on vitamin D supplementation in children and adults with CKD and after kidney transplantation. These were reviewed by a Delphi panel of members from relevant working groups of the ERA and ESPN. Key clinical practice points include recommendations to monitor for, and correct, vitamin D deficiency in children and adults with CKD and after kidney transplantation, targeting 25-hydroxyvitamin D levels >75 nmol/L (>30 ng/mL). While vitamin D supplementation appears well-tolerated and safe, it is recommended to avoid mega-doses (≥100 000 IU) and very high levels of 25 hydroxyvitamin D (>150-200 nmol/L, or 60-80 ng/mL) to reduce the risk of toxicity. Future clinical trials should investigate the benefit of vitamin D supplementation on patient-relevant outcomes in the setting of vitamin D deficiency across different stages of CKD.</p>","PeriodicalId":19078,"journal":{"name":"Nephrology Dialysis Transplantation","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2025-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143059184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low birth weight and chronic kidney disease with progression to kidney failure in children.","authors":"Fu-Shun Yen, James Cheng-Chung Wei, Wan-Yin Cheng, Chi-Ting Huang, Yi-Ling Wu, Suan-Heoh Teh, Chii-Min Hwu, Chih-Cheng Hsu","doi":"10.1093/ndt/gfaf018","DOIUrl":"https://doi.org/10.1093/ndt/gfaf018","url":null,"abstract":"<p><strong>Background and hypothesis: </strong>It is unclear if low birth weight (LBW), preterm birth and small for gestational age (SGA) could synergistically cause chronic kidney disease (CKD) and end-stage kidney disease (ESKD). This cohort study was conducted to examine their individual and combined impacts on the development of CKD and ESKD in childhood.</p><p><strong>Methods: </strong>From the Taiwan Maternal and Child Health Database, we identified 1 477 128 newborns born between January 1, 2009, and December 31, 2016. We used a multivariable Cox regression model to assess the excess risk of CKD and ESKD in children with LBW/preterm/SGA. They were followed from birth until the occurrence of outcomes or until December 31, 2018, with an average follow-up of 5.78 years.</p><p><strong>Results: </strong>This study included 1 361 071 infants with birth weight ≥ 2500 g (92.14%), 104 855 infants with low birth weight (1500 g to < 2500 g) (7.10%), 6 843 infants with very low birth weight (1000 g to < 1500 g) (0.46%), and 4 349 infants with extremely low birth weight (< 1000 g) (0.29%). The multivariable-adjusted model showed that male infants with low birth weight were associated with an increased risk of CKD (aHR 1.20, 95%CI 1.08-1.32) and ESKD (aHR 1.64, 95%CI 1.37-1.97). Female infants with LBW had an increased risk of CKD (aHR 1.18, 95%CI 1.06-1.32) and ESKD (aHR 1.31, 95%CI 1.09-1.58) than those without LBW. In addition to LBW, infants with preterm or SGA condition also had a significantly and synergistically increased risk of CKD and ESKD compared to full-term infants.</p><p><strong>Conclusion: </strong>We found children with LBW, preterm birth, or small for gestational age had a significantly increased risk of CKD and ESKD compared to children without intrauterine growth restriction.</p>","PeriodicalId":19078,"journal":{"name":"Nephrology Dialysis Transplantation","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143053028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Autonomic Nervous System and Inflammation in Chronic Kidney Disease.","authors":"Carmine Zoccali, Francesca Mallamaci, Mehmet Kanbay, Katherine R Tuttle, Peter Kotanko, Raffaele De Caterina, Guido Grassi, Giuseppe Mancia","doi":"10.1093/ndt/gfaf020","DOIUrl":"https://doi.org/10.1093/ndt/gfaf020","url":null,"abstract":"<p><p>The autonomic nervous system plays a crucial role in regulating physiological processes and maintaining homeostasis through its two branches: the sympathetic nervous system (SNS) and the parasympathetic nervous system. Dysregulation of the autonomic system, characterized by increased sympathetic activity and reduced parasympathetic tone, is a common feature in chronic kidney disease (CKD) and cardiovascular disease. This imbalance contributes to a pro-inflammatory state, exacerbating disease progression and increasing the risk for cardiovascular events. The sympathetic system promotes inflammation by releasing catecholamines, which activate adrenergic receptors on immune cells. The parasympathetic system exerts anti-inflammatory effects via the cholinergic anti-inflammatory pathway mediated by the vagus nerve. Targeting the autonomic system to restore the balance between the sympathetic and the parasympathetic components offers promising approaches to reduce inflammation and improve outcomes in CKD and cardiovascular disease. Beta-blockers, angiotensin-converting enzyme inhibitors (ACEi), and angiotensin II receptor blockers (ARBs) are pharmacological agents that modulate sympathetic activity and have shown anti-inflammatory effects. Lifestyle interventions, such as a healthy diet, physical exercise, mindfulness, and meditation, enhance parasympathetic activity and improve autonomic function. Vagus nerve stimulation has emerged as a promising therapy, demonstrating significant potential in reducing inflammation and improving clinical outcomes in various conditions, including CKD, myocardial infarction and stroke. Despite mixed results in heart failure trials, vagal nerve stimulation has consistently improved quality-of-life measures. Understanding the mechanisms underlying autonomic system regulation of inflammation can inform the development of novel therapeutic strategies to restore autonomic balance and improve patient outcomes in CKD and cardiovascular disease.</p>","PeriodicalId":19078,"journal":{"name":"Nephrology Dialysis Transplantation","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143053029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The use of lung-ultrasound monitoring and the risk of intradialysis hypotension in hemodialysis patients: an analysis in the context of a randomized clinical trial.","authors":"Claudia Torino, Francesca Mallamaci, Rocco Tripepi, Sabrina Mezzatesta, Giovanni Tripepi, Carmine Zoccali","doi":"10.1093/ndt/gfaf015","DOIUrl":"https://doi.org/10.1093/ndt/gfaf015","url":null,"abstract":"","PeriodicalId":19078,"journal":{"name":"Nephrology Dialysis Transplantation","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143053030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Haemodiafiltration Versus Haemodialysis on Vascular Access Patency when Starting Haemodialysis.","authors":"Mahoko Yoshida, Yujiro Maeoka, Akira Takahashi, Naoki Ishiuchi, Yosuke Osaki, Kensuke Sasaki, Takao Masaki","doi":"10.1093/ndt/gfaf017","DOIUrl":"https://doi.org/10.1093/ndt/gfaf017","url":null,"abstract":"<p><strong>Background: </strong>Haemodiafiltration (HDF) therapy improves the prognosis by reducing inflammation and oxidative stress, and improving endothelial function. These factors contribute to vascular access (VA) stenosis, one of the most common complications in patients on haemodialysis (HD) or HDF. This study aimed to assess the efficacy of HDF on VA patency.</p><p><strong>Methods: </strong>This multicentre, prospective, observational study with post-hoc analysis included 612 patients among 643 who underwent VA procedures and started dialysis between April 2012 and March 2021. Five hundred and sixteen patients were on HD from starting dialysis, while 96 switched to HDF after starting dialysis. One-to-one propensity score matching was performed to compare the 24-month patency rates of VA between groups by Kaplan-Meier and log-rank tests, and a Cox proportional hazard regression analysis was used to identify factors affecting patency rates.</p><p><strong>Results: </strong>There were 87 patients in each group. The 24-month primary patency rates were 74.2% for HDF and 47.7% for HD (P < 0.001). A multivariate Cox proportional hazards analysis showed that a history of cardiovascular disease (hazard ratio [HR] 2.29; 95% confidence interval [CI] 1.21-4.34, P = 0.01) and higher haemoglobin A1c values (HR 1.37; 95% CI 1.00-1.82, P = 0.04) were associated with poor 24-month primary patency. However, HDF (HR 0.30; 95% CI 0.16-0.56, P < 0.001) and use of statins (HR 0.50; 95% CI 0.27-0.94, P = 0.03) were associated with better patency. A stratified analysis showed that HRs for loss of VA patency were lower in patients with HDF than in those with HD in the subgroups of ≥ 65 years, male sex, radiocephalic arteriovenous fistula, a history of diabetes mellitus or cardiovascular disease, haemoglobin concentrations <10 g/dL, and albumin concentrations < 3.5 g/dL.</p><p><strong>Conclusions: </strong>HDF potentially improves VA patency rates compared with HD, even in patients with cardiovascular disease or diabetes, commonly associated with poor patency.</p>","PeriodicalId":19078,"journal":{"name":"Nephrology Dialysis Transplantation","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143040518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nephrectomy in Autosomal Dominant Polycystic Kidney Disease: A consensus statement of the ERA Genes & Kidney Working Group.","authors":"Paul Geertsema, Ron T Gansevoort, Mustafa Arici, Giovambattista Capasso, Emilie Cornec-Le-Gall, Monica Furlano, Daniel G Fuster, Flavia Galletti, Victoria Gómez-Dos-Santos, Maria Vanessa Perez-Gomez, Dimitrios Goumenos, Jan Halbritter, Eva Jambon, Uwe Korst, Anna M Leliveld, Mireia Musquera Felip, Arnaldo Figueiredo, Tom Nijenhuis, Jonathon Olsburgh, Robert A Pol, John A Sayer, Dirk Stippel, Roser Torra, Roman-Ulrich Müller, Niek F Casteleijn","doi":"10.1093/ndt/gfaf019","DOIUrl":"https://doi.org/10.1093/ndt/gfaf019","url":null,"abstract":"<p><p>A substantial number of patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) undergo a nephrectomy, especially in work-up for a kidney transplantation. Currently, there is no evidence-based algorithm to guide clinicians which patients should undergo nephrectomy, the optimal timing of this procedure, or the preferred surgical technique. This systematic review-based consensus statement aimed to answer important questions regarding nephrectomy in ADPKD. A literature review was performed and extended to a meta-analysis when possible. For this purpose, PubMed and EMBASE were searched up to May 2024. Fifty-four publications, describing a total of 2391 procedures, were included. In addition, an exploratory questionnaire was sent to urologists, nephrologists, and transplant-surgeons. These sources were used to develop practice points about indications, complications, mortality, timing, and technique of nephrectomy. In addition, data on renal embolization as a potential alternative to nephrectomy was explored and summarized. To reach consensus, practice points were defined and improved in three Delphi survey rounds by experts of the European Renal Association Working Group Genes & Kidney and the European Association of Urology Section of Transplantation Urology. A total of 23 practice points/statements were developed, all of which reached consensus. Among others, it was deemed that nephrectomy can be performed successfully for various indications and is an intermediate risk procedure with acceptable mortality and minimal impact on kidney graft function when performed before, in the same session or after transplantation. The complication rate seems to increase when the procedure is performed as an emergency. During the work-up for transplantation, patient complaints should be assessed routinely by questionnaires to indicate symptom burden. Deciding on the need for nephrectomy and exploring potential alternatives such as kidney embolization should be a process of shared decision making, preferably after multidisciplinary consultation.</p>","PeriodicalId":19078,"journal":{"name":"Nephrology Dialysis Transplantation","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143028872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A novel, dominant disease mechanism of distal renal tubular acidosis with specific variants in ATP6V1B1.","authors":"Myrte Daenen, Marguerite Hureaux, Emma Ashton, Francesca Becherucci, Ian Barry, Marcus Benz, Anna Bjerre, Andrew Buckton, Richard Caswell, Celia Duff-Farrier, Samantha Hayward, Joseph Mcallister, Anna Moczulska, Viviana Palazzo, Caroline Platt, Hitesh Prajapati, Moin Saleem, Karl-Peter Schlingmann, Francisco Telma, Marcin Zaniew, Francesco Emma, Detlef Bockenhauer","doi":"10.1093/ndt/gfaf016","DOIUrl":"https://doi.org/10.1093/ndt/gfaf016","url":null,"abstract":"<p><strong>Background and hypothesis: </strong>ATP6V1B1 encodes a subunit of the vacuolar H+-ATPase and pathogenic variants are associated with autosomal recessive distal renal tubular acidosis (dRTA) with deafness. Heterozygous variants predicted to affect a specific amino acid, Arg394, have been recurrently reported in dRTA but their significance has been unclear. We hypothesised that these variants are associated with a dominant disease mechanism.</p><p><strong>Methods: </strong>Retrospective analysis of cases identified in our genetic laboratories and through European nephrology organisations. Data regarding demographics, clinical presentation, laboratory findings, hearing and imaging studies of kidneys were collected from the index patient and, if available, from other family members. The potential disease mechanism was investigated through structural modelling in silico.</p><p><strong>Results: </strong>Twenty index patients in total were included, of which 19 carried the variant c.1181G>A; p.(Arg394Gln) and one c.1180C>G; p.(Arg394Gly). In 7 families, more than one member was affected and the variant segregated with the disease in those with available information (15 affected, 6 unaffected), except for the unaffected mother of 2 affected children, who was mosaic. In no patient was a second causative variant in trans identified. In 8 sporadic patients and 1 affected parent, the variant was confirmed to be de novo. Both variants are absent in gnomAD. Sensorineural hearing loss was reported in 8 of the 22 patients with available information. Structural modelling supports a crucial role for Arg394 in nucleotide binding.</p><p><strong>Conclusion: </strong>We provide strong evidence for the pathogenicity of heterozygous variants affecting Arg394 and thus a novel inheritance modus for ATP6V1B1-associated dRTA. Clinically, this form differs from the recessive one by the lower prevalence of hearing loss. The prominent position of Arg394 in the nucleotide binding fold of the H+-ATPase structure is consistent with a dominant negative mechanism. Our findings inform the diagnosis and management of patients with dRTA and variants of Arg394.</p>","PeriodicalId":19078,"journal":{"name":"Nephrology Dialysis Transplantation","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143008962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PLA2R autoantibodies, a multifaceted biomarker in nephrotic syndrome and membranous nephropathy.","authors":"Omar Ragy, Wessam Abass, Durga Anil K Kanigicherla, Bethany Shinkins, Janine Bestall, Natalie King, Paul Brenchley, Alison Smith, Patrick Hamilton","doi":"10.1093/ndt/gfaf012","DOIUrl":"https://doi.org/10.1093/ndt/gfaf012","url":null,"abstract":"<p><strong>Background and hypothesis: </strong>The PLA2R antibody test is a valuable first-line diagnostic tool for primary membranous nephropathy (MN), helping to identify PLA2R-related MN and potentially eliminating the need for a kidney biopsy in some individuals. By reducing the reliance on biopsies, the test streamlines diagnosis and improves patient care. However, determining the optimal PLA2R measurement method and cut-off is critical to maximising the benefits of the test and minimising any harms.</p><p><strong>Methods: </strong>A systematic review and meta-analysis were performed to evaluate serum- and urine-based biomarkers for distinguishing between PLA2R-related MN and non-PLA2R MN. Searches were conducted in databases including Medline, Embase, Cochrane Library, Scopus, Web of Science, INAHTA, and ClinicalTrials.gov. The methodology followed Cochrane-recommended guidelines for systematic reviews and meta-analyses, and the QUADAS-2 tool was utilised to assess the overall risk of bias.</p><p><strong>Results: </strong>Ninety one studies met the eligibility criteria for inclusion in the review. Of these, 38 studies reporting the accuracy of the PLA2R-Ab test using the EUROIMMUN ELISA method and 27 using the EUROIMMUN IF method were suitable for meta-analysis.. The pooled sensitivity and specificity of EUROIMMUN ELISA at a cut-off value of 20 RU/ml were 0.64 (95% CI: 0.56, 0.72) and 94.7% (95% CI: 90.5 - 97.1%),  respectively. The pooled sensitivity and specificity of EUROIMMUN IF at a threshold of 1:10 was 0.69 (95% CI: 0.637 - 0.739) and 0.98 (95% CI: 0.931 - 0.994), respectively. Risk of bias was higher for studies evaluating the IF compared to ELISA test. We also explored whether the timing of the index test had an impact on the pooled diagnostic accuracy results; no significant differences were found.</p><p><strong>Conclusions: </strong>By evaluating the specificity and sensitivity of EUROIMMUN ELISA PLA2R-Ab and immunofluorescence (IF), we demonstrate that at ELISA levels ≥20 RU/mL, alongside thorough secondary screening, a kidney biopsy may be unnecessary. However, lower or negative levels still warrant a biopsy.</p>","PeriodicalId":19078,"journal":{"name":"Nephrology Dialysis Transplantation","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143008964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"DEFENDER Trial: Dapagliflozin for Critically Ill Patients with Acute Organ Dysfunction -Implications for clinicians.","authors":"Jolanta Malyszko, Sophie De Seigneux, Vincenzo Cantaluppi, Stanislas Faguer, Joana Gameiro, Jose Antonio Lopes, Ana Sanz Bartolome, Turgay Saritas, Nicholas M Selby, Marlies Ostermann","doi":"10.1093/ndt/gfaf013","DOIUrl":"https://doi.org/10.1093/ndt/gfaf013","url":null,"abstract":"","PeriodicalId":19078,"journal":{"name":"Nephrology Dialysis Transplantation","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143008963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}